WikiSWOT
  • Home|
  • About Us|
  • How it Works|
  • Free SWOTs|
  • What's a SWOT?|
  • FAQ|
Pharmaceuticals & Biotech >> Abbott Laboratories SWOT Analysis:
Strengths
[list]
 [*] Global presence
 [*] Impressive growth forecast for Humira across a wide range of autoimmune disorders
 [*] Robust lipid management portfolio supported by a range of pipeline programs
 [*] Strong record of lifecycle management crucial in view of forthcoming patent expires
 [*]Innovation leader in the industry
 [*]Less employee turnover
 [*]Biggest warehouse in pharma industry
 [*]huge recognition and sales
 [*]very strong heritage
 [*]huge market share
 
Weaknesses
  • Upcoming patent expires
  • Narrow phase III pipeline, with little in the way of explosive launch opportunities
  • Late-stage pipeline currently offers limited expansion beyond existing therapeutic positions
Opportunities
  • License agreements
  • Launch of Flutiform
  • Positive outlook for diagnostics market
Threats
  • Unprecedented generic erosion exacerbated by ineffective product lifecycle launches
  • Government regulation
  • Industry consolidation

History: Version 16 (Newest), Version 15, Version 14, Version 13, Version 12, Version 11, Version 10, Version 9, Version 8, Version 7, Version 6, Version 5, Version 4, Version 3, Version 2, Version 1 (Oldest)



Go back to the SWOT analysis index, or start a discussion about Abbott Laboratories SWOT analysis by adding a comment below WikiSWOT Comments



 
Name
Email (not shared)
Website

Add comment